Wouter joined Forbion in 2019 as a Partner.
Wouter is currently General Partner at Forbion. He is responsible for deal origination, general portfolio management and divestment strategies, and focuses on Forbion's Growth Opportunities Funds, which concentrates on investing in late-stage life sciences companies.
Previously, Wouter was a Senior Trader and Executive Board member of the life sciences franchise at Kempen, a European boutique investment bank. In this role, he managed Kempen’s trading portfolio, and was involved in deal structuring and equity capital markets transactions, as well as larger block trades.
Until Gyroscope Therapeutics’ acquisition by Novartis for up to $1.5 billion, Wouter served as a member of Gyroscope Therapeutics’s board of directors. He has also served as a member of the board of directors of VectivBio from December of 2022 until its $1.2 billion acquisition by Ironwood. Wouter is currently on the board of Forbion’s SPAC vehicle, Forbion European Acquisition Corp. (NASDAQ: FRBN), in addition to being a board observer at NewAmsterdam Pharma N.V. (NASDAQ: NAMS). Wouter holds an M.Sc. in Business Administration from the University of Groningen, and a B.Sc. in International Business and Management from this same university.
At Forbion, investing goes beyond capital—it’s about conviction, discipline, and true partnership. We collaborate with exceptional entrepreneurs and scientific leaders who are redefining what’s possible in healthcare. I’m proud to support these visionaries in building companies that deliver real impact for patients and create lasting value for all stakeholders.
Portfolio
Companies worked on by Wouter Joustra
